Literature DB >> 24145714

Metabolomics in drug discovery and development.

D G Robertson1, U Frevert.   

Abstract

Metabolomics technology is being utilized across the spectrum of drug discovery and development; from the assessment of unanticipated biochemical sequelae of target engagement in transgenic models to monitoring media content to improve the efficiency of the manufacture of biologics, the impact of the technology is expanding dramatically. Applications critical for the pharmaceutical industry include translational medicine, biomarker discovery, and patient stratification. Technological innovation and cultural acceptance will be necessary to optimally use this powerful tool.

Entities:  

Mesh:

Year:  2013        PMID: 24145714     DOI: 10.1038/clpt.2013.120

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis.

Authors:  Caroline J Sands; Indra N Guha; Michael Kyriakides; Mark Wright; Olaf Beckonert; Elaine Holmes; William M Rosenberg; Muireann Coen
Journal:  Am J Gastroenterol       Date:  2014-12-23       Impact factor: 10.864

Review 2.  Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

Authors:  Naiem T Issa; Henri Wathieu; Abiola Ojo; Stephen W Byers; Sivanesan Dakshanamurthy
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

3.  Metabolomic signatures for liver tissue and cecum contents in high-fat diet-induced obese mice based on UHPLC-Q-TOF/MS.

Authors:  Hongying Cai; Zhiguo Wen; Kun Meng; Peilong Yang
Journal:  Nutr Metab (Lond)       Date:  2021-06-30       Impact factor: 4.169

4.  Drug repositioning for diabetes based on 'omics' data mining.

Authors:  Ming Zhang; Heng Luo; Zhengrui Xi; Ekaterina Rogaeva
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

5.  A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice.

Authors:  Wei Chen; Rong Gao; Xinni Xie; Zhibing Zheng; Haijing Li; Song Li; Fangting Dong; Lili Wang
Journal:  Sci Rep       Date:  2015-05-06       Impact factor: 4.379

Review 6.  Analytical methods in untargeted metabolomics: state of the art in 2015.

Authors:  Arnald Alonso; Sara Marsal; Antonio Julià
Journal:  Front Bioeng Biotechnol       Date:  2015-03-05

7.  Assessment of gold nanoparticles on human peripheral blood cells by metabolic profiling with 1H-NMR spectroscopy, a novel translational approach on a patient-specific basis.

Authors:  Martina Palomino-Schätzlein; Hermenegildo García; Patricia Gutiérrez-Carcedo; Antonio Pineda-Lucena; José Raul Herance
Journal:  PLoS One       Date:  2017-08-09       Impact factor: 3.240

Review 8.  Pharmacometabolomics in Early-Phase Clinical Development.

Authors:  T Burt; S Nandal
Journal:  Clin Transl Sci       Date:  2016-04-29       Impact factor: 4.689

Review 9.  Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti-tuberculosis activity.

Authors:  Naasson Tuyiringire; Deusdedit Tusubira; Jean-Pierre Munyampundu; Casim Umba Tolo; Claude M Muvunyi; Patrick Engeu Ogwang
Journal:  Clin Transl Med       Date:  2018-10-01

10.  Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity.

Authors:  Jaeseong Oh; Sojeong Yi; Namyi Gu; Dongseong Shin; Kyung-Sang Yu; Seo Hyun Yoon; Joo-Youn Cho; In-Jin Jang
Journal:  Genomics Inform       Date:  2018-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.